KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accumulated Expenses (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Accumulated Expenses for 15 consecutive years, with $126.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 46.5% year-over-year to $126.0 million, compared with a TTM value of $126.0 million through Dec 2025, up 46.5%, and an annual FY2025 reading of $126.0 million, up 46.5% over the prior year.
  • Accumulated Expenses was $126.0 million for Q4 2025 at Travere Therapeutics, up from $105.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $139.6 million in Q1 2024 and bottomed at $46.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $87.6 million, with a median of $84.8 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 62.75% in 2024, then plummeted 44.76% in 2025.
  • Year by year, Accumulated Expenses stood at $75.2 million in 2021, then increased by 27.35% to $95.7 million in 2022, then increased by 24.28% to $119.0 million in 2023, then decreased by 27.7% to $86.0 million in 2024, then soared by 46.5% to $126.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for TVTX at $126.0 million in Q4 2025, $105.8 million in Q3 2025, and $81.7 million in Q2 2025.